Key Points
- Charles Greg Guyer, BioMarin EVP, sold 16,486 shares on March 11 at an average of $60.46 for total proceeds of $996,743.56, cutting his stake by 17.09% to 79,953 shares worth about $4.83M.
- BioMarin shares were trading around $58.57 (down $0.50) with a one‑year range of $50.76–$73.18; the company has a market cap of $11.26B and a P/E of 32.9.
- Analysts' consensus is a Moderate Buy with an average price target of $90, though individual reports vary widely—from upgrades above $100 to downgrades into the $60 area and a sell rating.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) EVP Charles Greg Guyer sold 16,486 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total transaction of $996,743.56. Following the sale, the executive vice president directly owned 79,953 shares in the company, valued at $4,833,958.38. This trade represents a 17.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
BioMarin Pharmaceutical Stock Performance
Shares of NASDAQ BMRN traded down $0.50 during midday trading on Friday, hitting $58.57. The company's stock had a trading volume of 419,397 shares, compared to its average volume of 2,167,333. BioMarin Pharmaceutical Inc. has a 1-year low of $50.76 and a 1-year high of $73.18. The firm's fifty day moving average price is $58.98 and its 200-day moving average price is $56.34. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.50 and a current ratio of 5.21. The firm has a market cap of $11.26 billion, a P/E ratio of 32.90, a P/E/G ratio of 0.53 and a beta of 0.25.
Hedge Funds Weigh In On BioMarin Pharmaceutical
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Activest Wealth Management acquired a new position in shares of BioMarin Pharmaceutical during the 4th quarter valued at $26,000. Quent Capital LLC bought a new position in BioMarin Pharmaceutical during the third quarter valued at about $28,000. CIBC Private Wealth Group LLC boosted its stake in BioMarin Pharmaceutical by 38.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company's stock valued at $39,000 after buying an additional 179 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in BioMarin Pharmaceutical by 92.5% during the third quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 360 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new stake in BioMarin Pharmaceutical in the third quarter worth about $40,000. 98.71% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
BMRN has been the subject of a number of analyst reports. Sanford C. Bernstein boosted their price objective on BioMarin Pharmaceutical from $90.00 to $94.00 and gave the company an "outperform" rating in a research report on Wednesday, February 25th. Canaccord Genuity Group increased their price objective on shares of BioMarin Pharmaceutical from $98.00 to $104.00 and gave the stock a "buy" rating in a report on Thursday, February 26th. Leerink Partners cut BioMarin Pharmaceutical from an "outperform" rating to a "market perform" rating and cut their price target for the company from $82.00 to $60.00 in a report on Wednesday, December 3rd. Weiss Ratings reiterated a "sell (d)" rating on shares of BioMarin Pharmaceutical in a research report on Monday, December 29th. Finally, Guggenheim lowered their target price on BioMarin Pharmaceutical from $106.00 to $86.00 and set a "buy" rating on the stock in a research report on Wednesday, February 25th. Seventeen equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, BioMarin Pharmaceutical currently has an average rating of "Moderate Buy" and an average price target of $90.00.
View Our Latest Stock Report on BioMarin Pharmaceutical
About BioMarin Pharmaceutical
(
Get Free Report)
BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.
The company's commercial portfolio includes several approved therapies targeting inherited disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
